510(k) Report

510(k) · Cleared

Cleared

Gram Postitve Clindamycin

K122547510(k) TraditionalCleared Oct 15, 201255-day reviewClass II21 CFR 866.1645

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

bioMerieux, Inc. · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

Cleared on Oct 15, 2012 as substantially equivalent to K032766 (bioMerieux, Inc., 2003) after a 55-day review. Its family tree reaches back 1 generation to 2003. 5 later devices descend from it.

Decided
Oct 15, 2012
Review
55 days
Class
Class II
Product code
LON
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K032766 (2003). 5 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2014: 1 descendant cleared2019: 1 descendant cleared2021: 1 descendant cleared2022: 1 descendant cleared2020: 1 descendant clearedReference device: K050002 · Vitek 2 Compact · bioMerieux, Inc. · 2005 · recalledK032766 · Vitek 2 Gram Positive Linezolid · bioMerieux, Inc. · 2003200020052010201520202025
Descendants, by generation 1 generation forward: 1 descendant2 generations forward: 1 descendant3 generations forward: 3 descendants K032766 · Vitek 2 Gram Positive Linezolid · bioMerieux, Inc. · 20030
  1. Root · 1 generation backK032766 Vitek 2 Gram Positive LinezolidbioMerieux, Inc. · 2003
  2. This deviceK122547 Gram Postitve ClindamycinbioMerieux, Inc. · 2012
  3. Descendant · cites it directly · 4 of its ownK141149 Vitek 2 Ast GP CeftarolinebioMerieux, Inc. · 2014
  4. Descendant · 2 generations on · 3 of its ownK190616 VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL)bioMerieux, Inc. · 2019
  5. Descendant · 3 generations on · 0 of its ownK212243 VITEK 2 AST- Gram Positive Telavancin (<=0.015 - >=1 µg/mL)bioMerieux, Inc. · 2022
  6. Descendant · 3 generations on · 0 of its ownK202396 VITEK 2 AST-Gram Positive Fosfomycin (<=8 - >=256 ug/mL)bioMerieux, Inc. · 2021
  7. Descendant · 3 generations on · 0 of its ownK200590 VITEK 2 AST-Gram Positive Delafloxacin (<=0.015 - >=1 µg/mL)bioMerieux, Inc. · 2020

Most influential descendants

Showing 5 of 5 · See all
  • K141149Vitek 2 Ast GP CeftarolinebioMerieux, Inc. · 2014 · cites it directly4descendants
  • K190616VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL)bioMerieux, Inc. · 2019 · 2 generations on3descendants
  • K212243VITEK 2 AST- Gram Positive Telavancin (<=0.015 - >=1 µg/mL)bioMerieux, Inc. · 2022 · 3 generations on0descendants
  • K202396VITEK 2 AST-Gram Positive Fosfomycin (<=8 - >=256 ug/mL)bioMerieux, Inc. · 2021 · 3 generations on0descendants
  • K200590VITEK 2 AST-Gram Positive Delafloxacin (<=0.015 - >=1 µg/mL)bioMerieux, Inc. · 2020 · 3 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K032766Vitek 2 Gram Positive LinezolidbioMerieux, Inc.2003—
0 (this device)K122547Gram Postitve ClindamycinbioMerieux, Inc.2012—
+1K141149Vitek 2 Ast GP CeftarolinebioMerieux, Inc.2014—
+2K190616VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL)bioMerieux, Inc.2019—
+3K212243VITEK 2 AST- Gram Positive Telavancin (<=0.015 - >=1 µg/mL)bioMerieux, Inc.2022—
+3K202396VITEK 2 AST-Gram Positive Fosfomycin (<=8 - >=256 ug/mL)bioMerieux, Inc.2021—
+3K200590VITEK 2 AST-Gram Positive Delafloxacin (<=0.015 - >=1 µg/mL)bioMerieux, Inc.2020—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201410
201910
202010
202110
202210
FIG. 1 — Lineage of K122547, 2003–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LON device

  1. #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K032766Vitek 2 Gram Positive Linezolid
Summary page 1
…t Code LON Common Name: VITEF& 2 AST - GP Clindamycin C. Predicate Device: VITEK®2 Gram Positive Linezolid (k032766) D. 510(k) Summary: VITEK 2 AST - Gram Positive Clindamycin is designed for an antimicrobial susceptibility testing of St…
bioMerieux, Inc.2003—
†K050002Vitek 2 CompactbioMerieux, Inc.20056

Also cleared against K032766: 2 other devices →

What descends from it? (5)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K141149Vitek 2 Ast GP CeftarolinebioMerieux, Inc.20144

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K141149 (bioMerieux, Inc., 2014) has gone furthest, with 4 descendants of its own.
  • 2 other devices also cite its predicate K032766.

How does its category compare?

All LON devices

LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.

FDA decisions per year · LON

5in 2025

2007: 192008: 72009: 82010: 12011: 82012: 102013: 72014: 42016: 32017: 102018: 42019: 82020: 52021: 52022: 82023: 112024: 22025: 52026 (partial year): 4
2007high 19 (2007) · low 0 (2015)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LON

90in 2025

2007: 50 days median2008: 66 days median2009: 76 days median2011: 85 days median2012: 200 days median2013: 115 days median2014: 90 days median2016: 242 days median2017: 89 days median2018: 88 days median2019: 84 days median2020: 81 days median2021: 268 days median2022: 189 days median2023: 210 days median2025: 90 days median2026 (partial year): 146 days median
2007high 268 (2021) · low 50 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LON

1in 2025

2008: 12010: 1162011: 32012: 32014: 2, 2 Class I2016: 22017: 12018: 62019: 12020: 82022: 152024: 12025: 12026 (partial year): 6
2007high 116 (2010) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · LON

690in 2025

2007: 32008: 12010: 32011: 42012: 92013: 32014: 102015: 412016: 942017: 1972018: 5122019: 3152020: 2182021: 2322022: 1802023: 4532024: 4182025: 690
2007high 690 (2025) · low 0 (2009)2025

MAUDE reports naming product code LON, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007195003
200876611
200987600
20101—1163
201188534
20121020039
2013711503
20144902 (2)10
20150—041
20163242294
201710891197
20184886512
20198841315
20205818218
202152680232
2022818915180
2023112100453
20242—1418
20255901690
202641466—

What is it indicated for?

VITEK® 2 AST-GP Clindlamycin is designed for antimicrobial susceptibility testing of Staphylococcus aureus and Staphylococcus epiderniidis. VITEK 2 AST-GP Clindlamycin is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active against most strains of the microorganism listed below, according to…

Read the full statement (138 words)

VITEK® 2 AST-GP Clindlamycin is designed for antimicrobial susceptibility testing of Staphylococcus aureus and Staphylococcus epiderniidis. VITEK 2 AST-GP Clindlamycin is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Clindamycin has been shown to be active against most strains of the microorganism listed below, according to the FDA label for this antimicrobial.

Active in vitro and in clinical infections

Staphylococcus aureus (methicillin-susceptible strains) and Staphylococcus epiderniidis (methicillin-susceptible strains)

The VITEK® 2 Antimicrobial Susceptibility Test (AST.) is intended to be used with the VITEK® 2 and VITEK 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus apop., Enterococcus spp., Streptococcus agralactiae, and S. pneumoniae.

Indications for use as stated in the FDA summary.

Also cleared against K032766

2 other devices cite the same predicate.

  • K212849VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL)Biomérieux, Inc. · 2022
  • K050075Vitek 2 Gram Positive DaptomycinbioMerieux, Inc. · 2005

More from bioMerieux, Inc.

281 FDA decisions under this applicant name. See the company

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystembioMerieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025
  • K234012Vitek Compact ProbioMerieux, Inc. · 2025

Recent decisions in LON

The LON category page

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260619VITEK 2 AST-Streptococcus Cefepime (<=0.06 – >=4 µg/mL)Biomérieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)Biomerieux · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025

https://510kreport.com/device/K122547 · printed Nov 6, 2026

Cite this page

510(k) Report. “K122547: Gram Postitve Clindamycin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K122547

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026